請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73799
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭彥彬(YEN-PING KUO) | |
dc.contributor.author | Chi-Yu Hong | en |
dc.contributor.author | 洪志瑜 | zh_TW |
dc.date.accessioned | 2021-06-17T08:10:31Z | - |
dc.date.available | 2020-08-27 | |
dc.date.copyright | 2019-08-27 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-08-16 | |
dc.identifier.citation | 1.Baillie, R., S.T. Tan, and T. Itinteang, Cancer Stem Cells in Oral Cavity Squamous Cell Carcinoma: A Review. Front Oncol, 2017. 7: p. 112.
2.da Silva, S.D., et al., Advances and applications of oral cancer basic research. Oral Oncol, 2011. 47(9): p. 783-91. 3.Reya, T., et al., Stem cells, cancer, and cancer stem cells. Nature, 2001. 414(6859): p. 105-11. 4.Magee, J.A., E. Piskounova, and S.J. Morrison, Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell, 2012. 21(3): p. 283-96. 5.Dontu, G., et al., Stem cells in normal breast development and breast cancer. Cell Prolif, 2003. 36 Suppl 1: p. 59-72. 6.Brooks, M.D., M.L. Burness, and M.S. Wicha, Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer. Cell Stem Cell, 2015. 17(3): p. 260-71. 7.Jordan, C.T., M.L. Guzman, and M. Noble, Cancer stem cells. N Engl J Med, 2006. 355(12): p. 1253-61. 8.Ginestier, C., E. Charafe-Jauffret, and D. Birnbaum, Targeting breast cancer stem cells: fishing season open! Breast Cancer Res, 2010. 12(5): p. 312. 9.Yu, J., et al., Induced pluripotent stem cell lines derived from human somatic cells. Science, 2007. 318(5858): p. 1917-20. 10.Takahashi, K. and S. Yamanaka, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006. 126(4): p. 663-76. 11.Major, A.G., L.P. Pitty, and C.S. Farah, Cancer stem cell markers in head and neck squamous cell carcinoma. Stem Cells Int, 2013. 2013: p. 319489. 12.Rodda, D.J., et al., Transcriptional regulation of nanog by OCT4 and SOX2. J Biol Chem, 2005. 280(26): p. 24731-7. 13.Fu, T.Y., et al., Association of OCT4, SOX2, and NANOG expression with oral squamous cell carcinoma progression. J Oral Pathol Med, 2016. 45(2): p. 89-95. 14.Wang, J., et al., A protein interaction network for pluripotency of embryonic stem cells. Nature, 2006. 444(7117): p. 364-8. 15.Chiou, S.H., et al., Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res, 2008. 14(13): p. 4085-95. 16.Tsai, L.L., et al., Oct4 mediates tumor initiating properties in oral squamous cell carcinomas through the regulation of epithelial-mesenchymal transition. PLoS One, 2014. 9(1): p. e87207. 17.Patru, C., et al., CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer, 2010. 10: p. 66. 18.Tsai, L.L., et al., Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma. J Oral Pathol Med, 2011. 40(8): p. 621-8. 19.Lee, H.J., et al., Positive expression of NANOG, mutant p53, and CD44 is directly associated with clinicopathological features and poor prognosis of oral squamous cell carcinoma. BMC Oral Health, 2015. 15(1): p. 153. 20.Pozzi, V., et al., Identification and characterization of cancer stem cells from head and neck squamous cell carcinoma cell lines. Cell Physiol Biochem, 2015. 36(2): p. 784-98. 21.Liu, K., et al., The multiple roles for Sox2 in stem cell maintenance and tumorigenesis. Cell Signal, 2013. 25(5): p. 1264-71. 22.Chou, M.Y., et al., Sox2 expression involvement in the oncogenicity and radiochemoresistance of oral cancer stem cells. Oral Oncol, 2015. 51(1): p. 31-9. 23.Loh, Y.H., et al., The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet, 2006. 38(4): p. 431-40. 24.Huang, C.F., et al., Correlation of ALDH1, CD44, OCT4 and SOX2 in tongue squamous cell carcinoma and their association with disease progression and prognosis. J Oral Pathol Med, 2014. 43(7): p. 492-8. 25.Bourguignon, L.Y., et al., Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem, 2012. 287(39): p. 32800-24. 26.Yu, F., et al., Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene, 2011. 30(18): p. 2161-72. 27.Chen, L., et al., TRAF6 regulates tumour metastasis through EMT and CSC phenotypes in head and neck squamous cell carcinoma. J Cell Mol Med, 2018. 22(2): p. 1337-1349. 28.Monroe, M.M., et al., Cancer stem cells in head and neck squamous cell carcinoma. J Oncol, 2011. 2011: p. 762780. 29.Mack, B. and O. Gires, CD44s and CD44v6 expression in head and neck epithelia. PLoS One, 2008. 3(10): p. e3360. 30.Margaritescu, C., et al., The utility of CD44, CD117 and CD133 in identification of cancer stem cells (CSC) in oral squamous cell carcinomas (OSCC). Rom J Morphol Embryol, 2011. 52(3 Suppl): p. 985-93. 31.Oliveira, L.R., et al., CD44+/CD133+ immunophenotype and matrix metalloproteinase-9: Influence on prognosis in early-stage oral squamous cell carcinoma. Head Neck, 2014. 36(12): p. 1718-26. 32.Koukourakis, M.I., et al., Cancer stem cell phenotype relates to radio-chemotherapy outcome in locally advanced squamous cell head-neck cancer. Br J Cancer, 2012. 106(5): p. 846-53. 33.Kosunen, A., et al., CD44 expression and its relationship with MMP-9, clinicopathological factors and survival in oral squamous cell carcinoma. Oral Oncol, 2007. 43(1): p. 51-9. 34.Yeganeh, B., et al., Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacol Ther, 2014. 143(1): p. 87-110. 35.Ghavami, S., et al., Apoptosis, autophagy and ER stress in mevalonate cascade inhibition-induced cell death of human atrial fibroblasts. Cell Death Dis, 2012. 3: p. e330. 36.Goldstein, J.L. and M.S. Brown, Regulation of the mevalonate pathway. Nature, 1990. 343(6257): p. 425-30. 37.Thurnher, M., O. Nussbaumer, and G. Gruenbacher, Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res, 2012. 18(13): p. 3524-31. 38.Lewis, K.A., S.A. Holstein, and R.J. Hohl, Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo. Leuk Res, 2005. 29(5): p. 527-33. 39.Seeger, H., D. Wallwiener, and A.O. Mueck, Statins can inhibit proliferation of human breast cancer cells in vitro. Exp Clin Endocrinol Diabetes, 2003. 111(1): p. 47-8. 40.Jakobisiak, M., et al., Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci U S A, 1991. 88(9): p. 3628-32. 41.Koyuturk, M., M. Ersoz, and N. Altiok, Simvastatin induces proliferation inhibition and apoptosis in C6 glioma cells via c-jun N-terminal kinase. Neurosci Lett, 2004. 370(2-3): p. 212-7. 42.Rao, S., et al., Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene, 1998. 17(18): p. 2393-402. 43.Foster, R., et al., Identification of a novel human Rho protein with unusual properties: GTPase deficiency and in vivo farnesylation. Mol Cell Biol, 1996. 16(6): p. 2689-99. 44.Boureux, A., et al., Evolution of the Rho family of ras-like GTPases in eukaryotes. Mol Biol Evol, 2007. 24(1): p. 203-16. 45.Mackay, D.J., et al., Rho- and rac-dependent assembly of focal adhesion complexes and actin filaments in permeabilized fibroblasts: an essential role for ezrin/radixin/moesin proteins. J Cell Biol, 1997. 138(4): p. 927-38. 46.Oleksy, A., et al., The molecular basis of RhoA specificity in the guanine nucleotide exchange factor PDZ-RhoGEF. J Biol Chem, 2006. 281(43): p. 32891-7. 47.Adnane, J., et al., Suppression of rho B expression in invasive carcinoma from head and neck cancer patients. Clin Cancer Res, 2002. 8(7): p. 2225-32. 48.Burbelo, P., A. Wellstein, and R.G. Pestell, Altered Rho GTPase signaling pathways in breast cancer cells. Breast Cancer Res Treat, 2004. 84(1): p. 43-8. 49.Kimmelman, A.C., et al., Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci U S A, 2008. 105(49): p. 19372-7. 50.Wells, C.M., et al., Rho family GTPases are activated during HGF-stimulated prostate cancer-cell scattering. Cell Motil Cytoskeleton, 2005. 62(3): p. 180-94. 51.Hoang, M.V., M.C. Whelan, and D.R. Senger, Rho activity critically and selectively regulates endothelial cell organization during angiogenesis. Proc Natl Acad Sci U S A, 2004. 101(7): p. 1874-9. 52.Uchida, S., et al., The suppression of small GTPase rho signal transduction pathway inhibits angiogenesis in vitro and in vivo. Biochem Biophys Res Commun, 2000. 269(2): p. 633-40. 53.Pu, Y.S., et al., Down-regulated expression of RhoA in human conventional renal cell carcinoma. Anticancer Res, 2008. 28(4B): p. 2039-43. 54.Clark, E.A., et al., Genomic analysis of metastasis reveals an essential role for RhoC. Nature, 2000. 406(6795): p. 532-5. 55.Hakem, A., et al., RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev, 2005. 19(17): p. 1974-9. 56.Bellovin, D.I., et al., Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma. Oncogene, 2006. 25(52): p. 6959-67. 57.Simpson, K.J., A.S. Dugan, and A.M. Mercurio, Functional analysis of the contribution of RhoA and RhoC GTPases to invasive breast carcinoma. Cancer Res, 2004. 64(23): p. 8694-701. 58.Dietrich, K.A., et al., Specific induction of migration and invasion of pancreatic carcinoma cells by RhoC, which differs from RhoA in its localisation and activity. Biol Chem, 2009. 390(10): p. 1063-77. 59.Abecassis, I., et al., RhoA induces MMP-9 expression at CD44 lamellipodial focal complexes and promotes HMEC-1 cell invasion. Exp Cell Res, 2003. 291(2): p. 363-76. 60.Ma, L., J. Teruya-Feldstein, and R.A. Weinberg, Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 2007. 449(7163): p. 682-8. 61.Choy, E., et al., Endomembrane trafficking of ras: the CAAX motif targets proteins to the ER and Golgi. Cell, 1999. 98(1): p. 69-80. 62.Scheffzek, K., et al., The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science, 1997. 277(5324): p. 333-8. 63.Voon, D.C., et al., EMT-induced stemness and tumorigenicity are fueled by the EGFR/Ras pathway. PLoS One, 2013. 8(8): p. e70427. 64.Chan, L.H., et al., PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation. Cell Rep, 2018. 25(3): p. 690-701 e8. 65.Haghighi, F., et al., bFGF-mediated pluripotency maintenance in human induced pluripotent stem cells is associated with NRAS-MAPK signaling. Cell Commun Signal, 2018. 16(1): p. 96. 66.Moon, B.S., et al., Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/beta-catenin signaling. J Natl Cancer Inst, 2014. 106(2): p. djt373. 67.Farahani, E., et al., Cell adhesion molecules and their relation to (cancer) cell stemness. Carcinogenesis, 2014. 35(4): p. 747-59. 68.Lee, M.H., Y.S. Cho, and Y.M. Han, Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation. Stem Cells, 2007. 25(7): p. 1654-63. 69.Zhang, F.L. and P.J. Casey, Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem, 1996. 65: p. 241-69. 70.Gauthaman, K., C.Y. Fong, and A. Bongso, Statins, stem cells, and cancer. J Cell Biochem, 2009. 106(6): p. 975-83. 71.Ellenbroek, S.I. and J.G. Collard, Rho GTPases: functions and association with cancer. Clin Exp Metastasis, 2007. 24(8): p. 657-72. 72.Gunde-Cimerman, N. and A. Cimerman, Pleurotus fruiting bodies contain the inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase-lovastatin. Exp Mycol, 1995. 19(1): p. 1-6. 73.Liu, J.P., et al., Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev, 2006(1): p. CD004116. 74.Schaefer, E.J., et al., Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol, 2004. 93(1): p. 31-9. 75.Graaf, M.R., et al., Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev, 2004. 30(7): p. 609-41. 76.Simons, M., et al., Cholesterol and Alzheimer's disease: is there a link? Neurology, 2001. 57(6): p. 1089-93. 77.Wolozin, B., et al., Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol, 2000. 57(10): p. 1439-43. 78.Pazianas, M., et al., A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther, 2007. 29(8): p. 1548-58. 79.Mazurkiewicz, M. and T. Mazurkiewicz, Zoledronic Acid in the treatment of bone metastases from the breast and prostate carcinoma. Ortop Traumatol Rehabil, 2003. 5(3): p. 374-8. 80.Duivenvoorden, W.C., et al., Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer. Br J Cancer, 2007. 96(10): p. 1526-31. 81.Zheng, Y., et al., Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone, 2007. 40(2): p. 471-8. 82.Michigami, T., et al., The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat, 2002. 75(3): p. 249-58. 83.Dass, C.R. and P.F. Choong, Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol Cancer Ther, 2007. 6(12 Pt 1): p. 3263-70. 84.Molinuevo, M.S., L. Bruzzone, and A.M. Cortizo, Alendronate induces anti-migratory effects and inhibition of neutral phosphatases in UMR106 osteosarcoma cells. Eur J Pharmacol, 2007. 562(1-2): p. 28-33. 85.Hashimoto, K., et al., Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model. Cancer Res, 2005. 65(2): p. 540-5. 86.Cheng, Y.Y., et al., Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer, 2004. 42(5): p. 410-5. 87.Hashimoto, K., et al., Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem Biophys Res Commun, 2007. 354(2): p. 478-84. 88.Verdijk, R., et al., Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett, 2007. 246(1-2): p. 308-12. 89.Denoyelle, C., et al., New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer, 2003. 88(10): p. 1631-40. 90.van Beek, E., et al., Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun, 1999. 264(1): p. 108-11. 91.Niessner, H., et al., The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. J Invest Dermatol, 2011. 131(2): p. 468-79. 92.Kannel, W.B., Clinical misconceptions dispelled by epidemiological research. Circulation, 1995. 92(11): p. 3350-60. 93.Keys, A., et al., The seven countries study: 2,289 deaths in 15 years. Prev Med, 1984. 13(2): p. 141-54. 94.Kabakoff, B.D., J.W. Doyle, and A.A. Kandutsch, Relationships among dolichyl phosphate, glycoprotein synthesis, and cell culture growth. Arch Biochem Biophys, 1990. 276(2): p. 382-9. 95.Caruso, M.G., et al., Enhanced 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in human colorectal cancer not expressing low density lipoprotein receptor. Anticancer Res, 1999. 19(1A): p. 451-4. 96.Littman, M.L., T. Taguchi, and E.H. Mosbach, Effect of cholesterol-free, fat-free diet and hypocholesteremic agents on growth of transplantable animal tumors. Cancer Chemother Rep, 1966. 50(1): p. 25-45. 97.Bos, J.L., ras oncogenes in human cancer: a review. Cancer Res, 1989. 49(17): p. 4682-9. 98.White, M.A., et al., Multiple Ras functions can contribute to mammalian cell transformation. Cell, 1995. 80(4): p. 533-41. 99.Casey, P.J. and M.C. Seabra, Protein prenyltransferases. J Biol Chem, 1996. 271(10): p. 5289-92. 100.Kohl, N.E., et al., Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci U S A, 1994. 91(19): p. 9141-5. 101.Berenson, J.R., et al., Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer, 2001. 91(7): p. 1191-200. 102.Koto, K., et al., Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents. Oncol Rep, 2010. 24(1): p. 233-9. 103.Koto, K., et al., Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model. Cancer Lett, 2009. 274(2): p. 271-8. 104.Tamura, T., et al., Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines. Oncol Rep, 2011. 25(4): p. 1139-43. 105.Ullen, A., et al., Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines. Scand J Urol Nephrol, 2009. 43(2): p. 98-103. 106.Koizumi, M., et al., Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells. Eur J Haematol, 2007. 79(5): p. 382-91. 107.Ullen, A., et al., Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol, 2005. 44(6): p. 644-50. 108.Jagdev, S.P., et al., The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer, 2001. 84(8): p. 1126-34. 109.Ozturk, O.H., et al., Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study. Cell Biol Int, 2007. 31(9): p. 1069-71. 110.Yamada, J., et al., Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J Surg Res, 2009. 151(1): p. 115-20. 111.Di Salvatore, M., et al., Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Prolif, 2011. 44(2): p. 139-46. 112.Tsai, S.H., et al., Zoledronate inhibits ischemia-induced neovascularization by impairing the mobilization and function of endothelial progenitor cells. PLoS One, 2012. 7(7): p. e41065. 113.Clezardin, P., et al., In vitro and in vivo antitumor effects of bisphosphonates. Curr Med Chem, 2003. 10(2): p. 173-80. 114.Hiraga, T., et al., Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res, 2004. 10(13): p. 4559-67. 115.Boissier, S., et al., Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res, 1997. 57(18): p. 3890-4. 116.Al-Hajj, M., et al., Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A, 2003. 100(7): p. 3983-8. 117.Ben-Porath, I., et al., An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet, 2008. 40(5): p. 499-507. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73799 | - |
dc.description.abstract | 衛生福利部公佈的106年癌症登記報告指出,口腔癌為臺灣男性十大癌症死亡率的第五位。儘管近幾年口腔癌在診斷及治療技術上有改進,但病人五年存活率並未有顯著改善,失敗的主要原因之一為能夠自我更新的癌幹細胞(cancerstem cells, CSCs)存在,雖只佔一腫瘤小部份,但具持續分裂、分化的能力。近期的研究發現癌幹細胞對常規治療有抗藥性,導致癌症在治療後容易出現復發情形。由於癌幹細胞會表現大量的胚胎幹細胞調控蛋白,如果能夠有效抑制這些特定蛋白,便可消除癌幹細胞對化學藥物及放射治療之抗性。 Lovastatin為膽固醇
生合成途徑mevalonate途徑HMG-CoA reductase的抑制劑。近年文獻指出statin類的藥物除了有降血脂的功用外,對於惡性腫瘤如大腸癌、頭頸癌、乳癌、肺癌具有抑制增殖與轉移或促進細胞凋亡的作用。 郭教授實驗室先前已成功自口腔癌細胞株中培養出呈聚球狀(sphere)的口腔癌幹細胞。本研究是探討lovastatin做為未來抑制口腔癌幹細胞藥物的潛力。我們首先利用不同濃度的lovastatin處理SAS,經MTT結果發現,在濃度1~5M之間不影響SAS 聚球細胞存活率(IC50=10M); 且濃度1~50M之間的lovastatin不影響正常纖維母細胞的細胞存活率。接著在sphere forming assay中,lovastatin的濃度越高,形成sphere的數量與大小隨之減少。在invasion assay中,5M的lovastatin,幾乎可以完全抑制SAS 聚球細胞的侵襲。qPCR和Western blotting發現5M lovastatin 與 2.5 M的mevalonate途徑FPP synthase 抑制劑zoledronic acid幾乎可以完全抑制SAS 聚球細胞的癌幹細胞相關基因如OCT4、SOX2 、KLF4 的表現。Lovastatin 可能經由抑制ras 癌蛋白geranylgeranylation 而具有未來抑制口腔癌幹細胞藥物的潛力。 | zh_TW |
dc.description.abstract | According to the 106-year cancer registration report released by the Ministry of Health and Welfare, oral cancer is the fifth leading cause of death among men in
Taiwan . Despite the improvement in the diagnosis and treatment of oral cancer in recent years, the five-year survival rate of patients has not improved significantly. Treatment failure and recurrence are attributed to cancer stem cells. Cancer stem cells, a small part of cancer cells, are highly tumorigenic cancer cells that are capable of self-renewal and asymmetric division leads to differentiation into various heterogeneous cancer cells to cause tumor formation. It is worth noting that recent studies have shown that cancer stem cells are resistant to conventional treatment and drive local recurrence and metastasis. Since cancer stem cells would highly express embryonic stem cell proteins, if we can effectively inhibit these specific proteins, we would eliminate the resistance of cancer stem cells to chemical drugs and radiation therapy. Lovastatin, the HMG-CoA reductase inhibitors, not only lower serum cholesterol but also have antitumor effects in many cancer cell such as colorectal cancer, head and neck cancer, breast cancer and lung cancer in recent years. Professor Kuo’s lab has previously successfully cultured oral cancer stem cells in a sphere form from oral cancer cell lines. This study explores the potential of lovastatin for suppressing oral cancer stem cells in the future. First, we treat SAS cell line with different concentrations of lovastatin, MTT results found that the concentration of 1~5M does not affect the cell viability of SAS sp (IC50=10M), and lovastatin at a concentration of 1~50 M does not affect the cell viability of normal fibroblasts; then in the sphere forming assay, the higher the concentration of lovastatin, the formation of sphere number and size decreased; in the invasion assay, 5 M lovastatin almost completely inhibited the invasion of SAS sp, and we further treated SAS sp with lovastatin and zoledronic acid(FPP synthase inhibitor), using qPCR and western blotting we found that 5M lovastatin and 2.5M zoledronic acid inhibit the expression of stemness-associated genes such as OCT4, SOX2 and KLF4. Lovastatin have the potential to inhibit oral cancer stem cell by inhibiting the geranylgeranylation of Ras oncogene. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T08:10:31Z (GMT). No. of bitstreams: 1 ntu-108-R04450010-1.pdf: 2269007 bytes, checksum: 1598a69031222d951ac6e0a3c6bfb29e (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 第一章導論.................................................................................................................. 1
第一節 口腔癌................................................................................................ 1 1-1 口腔癌簡介 ............................................................................................. 1 1-2 口腔癌的診斷與分期 ............................................................................. 2 1-3 口腔癌治療 ............................................................................................. 4 第二節 癌幹細胞................................................................................................ 6 2-1 癌幹細胞(Cancer stem cells) .................................................................. 6 2-2 胚胎幹細胞標誌物(Embryonic Stem Cell (ESC) Marker) .................... 7 2-3 癌症幹細胞標誌物(CANCER STEM MARKER)................................. 9 第三節Mevalonate 途徑 ................................................................................... 11 3-1 Mevalonate 途徑 .................................................................................. 11 3-2 Mevalonate 途徑與癌症 ...................................................................... 11 3-3 Small Rho GTPase Proteins .................................................................. 12 3-4 Ras 蛋白 ................................................................................................ 14 3-5 Isoprenoids 活化Rho GTPases 調節細胞幹性 .................................. 15 3-6 影響mevalonate 途徑的藥物 ............................................................. 16 第四節Lovastatin ............................................................................................... 18 4-1 Lovastatin 藥物與其應用 ..................................................................... 18 4-2 Lovastatin 藥理 ..................................................................................... 18 4-3 Lovastatin 之抗腫瘤機制 ..................................................................... 19 第五節Zoledronic acid ...................................................................................... 21 5-1 Zoledronic acid 藥物與其應用 ............................................................. 21 5-2 Zoledronic acid 之抗腫瘤機制 ............................................................. 21 第二章 實驗目的........................................................................................................ 24 第三章材料與方法.................................................................................................... 25 第一節 細胞株與細胞培養.......................................................................... 25 1-1 細胞株的培養 ....................................................................................... 25 1-2 繼代培養 .............................................................................................. 25 1-3 腫瘤球體形成培養(tumorsphere formation) ....................................... 26 第二節 藥物處理.......................................................................................... 26 2-1 抑制劑使用資料 .................................................................................. 26 第三節 細胞存活率試驗(MTT) assay ....................................................... 27 vii 第四節 Sphere Forming Assay ..................................................................... 27 第五節 Invasion Assay ................................................................................. 28 第六節即時定量聚合酶連鎖反應(qPCR) ....................................................... 28 6-1 RNA 萃取與定量 .................................................................................. 28 6-2 反轉錄 .................................................................................................. 29 6-3 即時定量聚合酶連鎖反應 .................................................................. 29 第七節西方墨點法(Western blot) ..................................................................... 30 7-1 蛋白質萃取 .......................................................................................... 30 7-2 配置膠體 .............................................................................................. 30 7-3 電泳分析 .............................................................................................. 30 7-4 蛋白質的轉漬 ...................................................................................... 31 7-5 抗體的使用 .......................................................................................... 31 7-6 顯影呈色 .............................................................................................. 32 第四章結果................................................................................................................ 33 Lovastatin 抑制SAS sp 細胞生長 ...................................................................... 33 Zoledronic acid 抑制SAS sp 細胞生長 ............................................................. 33 Lovastatin 不影響正常纖維母細胞生長 ............................................................ 33 非貼附培養系統誘導癌細胞幹性相關基因表現增加...................................... 34 Lovastatin、zoledronic acid 降低SAS sp 球狀形成的大小 ............................. 34 Lovastatin、zoledronic acid 降低SAS sp 球狀形成的顆數與大小 ................. 34 Lovastatin 抑制SAS sp 細胞KLF4、OCT4、SOX2 基因與蛋白表現 .......... 35 Zelodronic acid 抑制SAS sp 細胞KLF4、OCT4、SOX2 蛋白表現 .............. 35 Lovastatin 降低SAS sp 侵襲的能力 .................................................................. 35 第五章 討論.............................................................................................................. 36 第六章 圖與表.......................................................................................................... 38 第七章 References .................................................................................................... 52 | |
dc.language.iso | zh-TW | |
dc.title | Lovastatin抑制口腔癌幹細胞幹性基因表現與侵襲能力 | zh_TW |
dc.title | Lovastatin inhibits stemness genes and invasion of oral cancer stem cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 周涵怡,張瑞青 | |
dc.subject.keyword | 口腔癌,癌幹細胞,洛伐他汀,甲羥戊酸途徑, | zh_TW |
dc.subject.keyword | oral cancer,cancer stem cell,stemness,lovastatin,mevalonate pathway, | en |
dc.relation.page | 60 | |
dc.identifier.doi | 10.6342/NTU201903808 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-08-16 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 口腔生物科學研究所 | zh_TW |
顯示於系所單位: | 口腔生物科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 2.22 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。